TapewireFind a company

person · Reporting owner

SHAH MAHENDRA

Disclosed activity across 5 companies

Tapewire entity
74416
SEC CIK
0001255449

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Bolt Biotherapeutics, Inc.BOLT · Entity 8082DirectorJune 12, 2024June 14, 2024
IPI Legacy Liquidation CoIMPL · Entity 15659DirectorJune 16, 2023June 20, 2023
Q32 Bio Inc.FIXX · Entity 5594DirectorApril 02, 2018May 16, 2018
SOLENO THERAPEUTICS INCSLNO · Entity 46432DirectorJune 11, 2018June 18, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Bolt Biotherapeutics, Inc.

Report date June 12, 2024 · Filed June 14, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.77 · Expires 2034-06-11Direct22,000 Reported balance After 2024-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2024-06-12 · Grant · Acquired 22,000 · Balance 22,000

F1: The shares subject to the option will vest on the earlier of June 12, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option will vest on the earlier of June 12, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.

IPI Legacy Liquidation Co

Report date June 16, 2023 · Filed June 20, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2033-06-15Direct13,222 Reported balance After 2023-06-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-06-16 · Grant · Acquired 13,222 · Balance 13,222

F1: The option is 100% vested on June 16, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: The option is 100% vested on June 16, 2024.

Q32 Bio Inc.

Report date April 02, 2018 · Filed May 16, 2018 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee footnote909,742 Reported balance After 2018-04-02 transaction · row 1 Amendment: may correct only part of an earlier disclosure.
1 source row

Row 1 · 2018-04-02 · Grant · Acquired 250,000 · Balance 909,742

F1: The securities reported herein are held of record by Vivo Panda Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D., is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. Each of Vivo LLC and Dr. Shah disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported herein are held of record by Vivo Panda Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D., is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. Each of Vivo LLC and Dr. Shah disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.

SOLENO THERAPEUTICS INC

Report date June 11, 2018 · Filed June 18, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.04 · Expires 2028-06-11Direct15,931 Reported balance After 2018-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2018-06-11 · Grant · Acquired 15,931 · Balance 15,931

F1: One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary on the Vesting Commencement Date (which is June 11, 2018) or the date of the 2018 Annual Shareholder Meeting, whichever is earlier.

Filing footnotes · ownership attribution and instrument terms

F1: One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary on the Vesting Commencement Date (which is June 11, 2018) or the date of the 2018 Annual Shareholder Meeting, whichever is earlier.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Verona Pharma plc

Report date October 07, 2025 · Filed October 08, 2025

Section 16 reporting ended · disclosed 2025-10-08. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect0 Last balance in matching sequence After 2025-10-07 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rows

Row 1 · 2025-10-07 · Disposition to issuer · Disposed 93,472 · Balance 0

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco").

F3: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration").

Row 2 · 2025-10-07 · Exercise / conversion · Acquired 72,000 · Balance 72,000

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.

Row 3 · 2025-10-07 · Disposition to issuer · Disposed 72,000 · Balance 0

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.

Restricted Share UnitSEC Table II · derivative / convertible securityDirect0 Reported balance After 2025-10-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2025-10-07 · Exercise / conversion · Disposed 72,000 · Balance 0

F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.

F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2032-04-27Direct0 Reported balance After 2025-10-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2025-10-07 · Disposition to issuer · Disposed 200,000 · Balance 0

F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.67 · Expires 2033-04-27Direct0 Reported balance After 2025-10-07 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2025-10-07 · Disposition to issuer · Disposed 96,000 · Balance 0

F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.93 · Expires 2034-04-28Direct0 Reported balance After 2025-10-07 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2025-10-07 · Disposition to issuer · Disposed 240,000 · Balance 0

F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2031-08-08Direct0 Reported balance After 2025-10-07 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2025-10-07 · Disposition to issuer · Disposed 64,000 · Balance 0

F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco").

F3: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration").

F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.

F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.

F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 07, 2025 Filed Oct 8, 2025 16:38 UTC Verona Pharma plc VRNA · Entity 74409 Disposition to issuerShare Options (Right to Buy) · Derivative 64,000 Not disclosed Strike: $0.78 Not disclosed
Disclosure

SEC source: 0001104659-25-097956 · tm2528014-8_4seq1.xml · derivative · entry 8

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 64,000 shares

Expires 2031-08-08

F6 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

F6 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Read SEC document
October 07, 2025 Filed Oct 8, 2025 16:38 UTC Verona Pharma plc VRNA · Entity 74409 Disposition to issuerShare Options (Right to Buy) · Derivative 240,000 Not disclosed Strike: $1.93 Not disclosed
Disclosure

SEC source: 0001104659-25-097956 · tm2528014-8_4seq1.xml · derivative · entry 7

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 240,000 shares

Expires 2034-04-28

F6 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

F6 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Read SEC document
October 07, 2025 Filed Oct 8, 2025 16:38 UTC Verona Pharma plc VRNA · Entity 74409 Disposition to issuerShare Options (Right to Buy) · Derivative 96,000 Not disclosed Strike: $2.67 Not disclosed
Disclosure

SEC source: 0001104659-25-097956 · tm2528014-8_4seq1.xml · derivative · entry 6

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 96,000 shares

Expires 2033-04-27

F6 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

F6 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Read SEC document
October 07, 2025 Filed Oct 8, 2025 16:38 UTC Verona Pharma plc VRNA · Entity 74409 Disposition to issuerShare Options (Right to Buy) · Derivative 200,000 Not disclosed Strike: $0.50 Not disclosed
Disclosure

SEC source: 0001104659-25-097956 · tm2528014-8_4seq1.xml · derivative · entry 5

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 200,000 shares

Expires 2032-04-27

F6 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

F6 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Read SEC document
October 07, 2025 Filed Oct 8, 2025 16:38 UTC Verona Pharma plc VRNA · Entity 74409 Exercise / conversionRestricted Share Unit · Derivative 72,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-25-097956 · tm2528014-8_4seq1.xml · derivative · entry 4

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 72,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · security: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.

F4 · derivative.exercise_price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.

F4 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.

F4 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.

F4 · derivative.expiration_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.

F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Read SEC document
October 07, 2025 Filed Oct 8, 2025 16:38 UTC Verona Pharma plc VRNA · Entity 74409 Disposition to issuerOrdinary Shares 72,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-25-097956 · tm2528014-8_4seq1.xml · nonDerivative · entry 3

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F4 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.

Read SEC document
October 07, 2025 Filed Oct 8, 2025 16:38 UTC Verona Pharma plc VRNA · Entity 74409 Exercise / conversionOrdinary Shares 72,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-25-097956 · tm2528014-8_4seq1.xml · nonDerivative · entry 2

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F4 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.

Read SEC document
October 07, 2025 Filed Oct 8, 2025 16:38 UTC Verona Pharma plc VRNA · Entity 74409 Disposition to issuerOrdinary Shares 93,472 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-25-097956 · tm2528014-8_4seq1.xml · nonDerivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2 · price: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco").

F3 · price: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration").

Read SEC document
August 01, 2025 Filed Aug 5, 2025 20:18 UTC Verona Pharma plc VRNA · Entity 74409 Exercise / conversionRestricted Stock Units · Derivative 24,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-074384 · tm2522566-3_4seq1.xml · derivative · entry 3

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,000

Underlying: Ordinary Shares · 24,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · security: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.

F5 · derivative.exercise_price: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.

F6 · derivative.exercise_date: The RSUs vest as to 25% of the total shares on each of August 1, 2025, November 1, 2025, February 1, 2026 and May 1, 2026 subject to the Reporting Person's continued service to the Issuer on each vesting date.

F5 · derivative.expiration_date: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.

F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Read SEC document
August 01, 2025 Filed Aug 5, 2025 20:18 UTC Verona Pharma plc VRNA · Entity 74409 SaleOrdinary Shares 3,608 $13.14 $47,422.47
Disclosure

SEC source: 0001104659-25-074384 · tm2522566-3_4seq1.xml · nonDerivative · entry 2

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,472

F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2 · kind: The sale reported in the Form 4 represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the Reporting Person's tax withholding obligation upon the vesting of the restricted stock units ("RSUs").

F3 · price: The price reported represents the sale price of the ADSs divided by eight (8).

F4 · balance_after: Consists of 93,472 Ordinary Shares represented by 11,684 ADSs.

Read SEC document
August 01, 2025 Filed Aug 5, 2025 20:18 UTC Verona Pharma plc VRNA · Entity 74409 Exercise / conversionOrdinary Shares 24,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-074384 · tm2522566-3_4seq1.xml · nonDerivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,080

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Read SEC document
April 25, 2025 Filed Apr 29, 2025 17:16 UTC Verona Pharma plc VRNA · Entity 74409 GrantRestricted Share Units · Derivative 96,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-041399 · tm2513544-8_4seq1.xml · derivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,000

Underlying: Ordinary Shares · 96,000 shares

Expires not disclosed

F1 · security: Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.

F1 · derivative.exercise_price: Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.

F1 · shares: Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.

F2 · derivative.exercise_date: The RSUs vest as to 25% of the total shares on each of August 1, 2025, November 1, 2025, February 1, 2026 and May 1, 2026 subject to the Reporting Person's continued service to the Issuer on each vesting date.

F1 · derivative.expiration_date: Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.

Read SEC document
June 12, 2024 Filed Jun 14, 2024 23:04 UTC Bolt Biotherapeutics, Inc. BOLT · Entity 8082 GrantStock Option (Right to Buy) · Derivative 22,000 $0.00 Strike: $0.77 $0.00
Disclosure

SEC source: 0000950170-24-073918 · ownership.xml · derivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2034-06-11

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 12, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.

Read SEC document
April 29, 2024 Filed Apr 30, 2024 16:17 UTC Verona Pharma plc VRNA · Entity 74409 GrantShare Options (Right to Buy) · Derivative 240,000 $0.00 Strike: $1.93 $0.00
Disclosure

SEC source: 0001104659-24-054950 · tm2412993-7_4seq1.xml · derivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 240,000

Underlying: Ordinary Shares · 240,000 shares

Expires 2034-04-28

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer.

F1 · shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer.

F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% on each of July 29, 2024, October 29, 2024, January 29, 2025 and April 29, 2025.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer.

Read SEC document
June 16, 2023 Filed Jun 20, 2023 18:38 UTC IPI Legacy Liquidation Co IMPL · Entity 15659 GrantStock Option (right to buy) · Derivative 13,222 $0.00 Strike: $1.34 $0.00
Disclosure

SEC source: 0001209191-23-038601 · doc4.xml · derivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,222

Underlying: Common Stock · 13,222 shares

Expires 2033-06-15

F1 · derivative.exercise_date: The option is 100% vested on June 16, 2024.

Read SEC document
June 12, 2023 Filed Jun 14, 2023 21:21 UTC Bolt Biotherapeutics, Inc. BOLT · Entity 8082 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $1.63 $0.00
Disclosure

SEC source: 0001209191-23-037117 · doc4.xml · derivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2033-06-11

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 12, 2024 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.

Read SEC document
April 28, 2023 Filed Apr 28, 2023 16:23 UTC Verona Pharma plc VRNA · Entity 74409 GrantShare Options (Right to Buy) · Derivative 96,000 $0.00 Strike: $2.67 $0.00
Disclosure

SEC source: 0001104659-23-053020 · tm2314094-8_4seq1.xml · derivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,000

Underlying: Ordinary Shares · 96,000 shares

Expires 2033-04-27

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F1 · shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% on each of July 28, 2023, October 28, 2023, January 28, 2024 and April 28, 2024.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Read SEC document
June 16, 2022 Filed Jun 17, 2022 17:05 UTC IPI Legacy Liquidation Co IMPL · Entity 15659 GrantStock Option (right to buy) · Derivative 12,789 $0.00 Strike: $8.65 $0.00
Disclosure

SEC source: 0001209191-22-037957 · doc4.xml · derivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,789

Underlying: Common Stock · 12,789 shares

Expires 2032-06-15

F1 · derivative.exercise_date: The option is 100% vested on June 16, 2023.

Read SEC document
June 10, 2022 Filed Jun 10, 2022 22:28 UTC Bolt Biotherapeutics, Inc. BOLT · Entity 8082 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $1.99 $0.00
Disclosure

SEC source: 0001209191-22-036090 · doc4.xml · derivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-06-09

F1 · derivative.exercise_date: The shares subject to this option shall vest on the one-year anniversary of June 10, 2022 (the "Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date; provided, however that the option will vest in full upon a change in control of the Issuer.

Read SEC document
April 28, 2022 Filed Apr 29, 2022 16:42 UTC Verona Pharma plc VRNA · Entity 74409 GrantShare Options (Right to Buy) · Derivative 200,000 $0.00 Strike: $0.50 $0.00
Disclosure

SEC source: 0001104659-22-053678 · tm2214046-1_4seq1.xml · derivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Ordinary Shares · 200,000 shares

Expires 2032-04-27

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F1 · shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% on each of July 28, 2022, October 28, 2022, January 28, 2023 and April 28, 2023.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Read SEC document
March 24, 2022 Filed Mar 28, 2022 19:18 UTC Bolt Biotherapeutics, Inc. BOLT · Entity 8082 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $3.03 $0.00
Disclosure

SEC source: 0000899243-22-012456 · doc4.xml · derivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-03-23

F1 · derivative.exercise_date: The shares subject to this option shall vest on the one-year anniversary of June 10, 2021 (the "Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date; provided, however that the option will vest in full upon a change in control of the Issuer.

Read SEC document
August 09, 2021 Filed Aug 10, 2021 16:45 UTC Verona Pharma plc VRNA · Entity 74409 GrantShare Options (Right to Buy) · Derivative 64,000 $0.00 Strike: $0.78 $0.00
Disclosure

SEC source: 0001104659-21-102893 · tm2124631-6_4seq1.xml · derivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,000

Underlying: Ordinary Shares · 64,000 shares

Expires 2031-08-08

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F1 · shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% on August 9, 2021, 25% on November 1, 2021, 25% on February 1, 2022 and 25% on May 1, 2022.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Read SEC document
July 11, 2021 Filed Jul 13, 2021 17:10 UTC IPI Legacy Liquidation Co IMPL · Entity 15659 GrantStock Option (right to buy) · Derivative 11,500 $0.00 Strike: $9.96 $0.00
Disclosure

SEC source: 0001209191-21-046571 · doc4.xml · derivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,500

Underlying: Common Stock · 11,500 shares

Expires 2031-07-10

F1 · derivative.exercise_date: The option is 100% vested on July 11, 2022.

Read SEC document
May 04, 2021 Filed May 5, 2021 17:03 UTC Verona Pharma plc VRNA · Entity 74409 SaleOrdinary Shares 10,680 $0.84 $8,968.00
Disclosure

SEC source: 0001104659-21-061801 · tm2115267-3_4seq1.xml · nonDerivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,080

F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of Restricted Stock Units.

F3 · price: The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $0.8063 to $0.8525. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3.

F4 · balance_after: Consists of 73,080 Ordinary Shares represented by 9,135 ADSs.

Read SEC document
February 09, 2021 Filed Feb 9, 2021 20:33 UTC Bolt Biotherapeutics, Inc. BOLT · Entity 8082 OtherWarrant (Right to Buy) · Derivative 17,711 $0.00 Strike: $0.07 $0.00
Disclosure

SEC source: 0001209191-21-008753 · doc4.xml · derivative · entry 7

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Vivo PANDA Fund, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 17,711 shares

Expires 2028-07-26

F5 · derivative.exercise_date: The shares subject to this warrant were fully vested prior to exercise.

F2 · ownership.nature: The securities reported herein are held of record by Vivo PANDA Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. The Reporting Person is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
February 09, 2021 Filed Feb 9, 2021 20:33 UTC Bolt Biotherapeutics, Inc. BOLT · Entity 8082 ConversionSeries B Preferred Stock · Derivative 472,296 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-008753 · doc4.xml · derivative · entry 6

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Vivo PANDA Fund, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 472,296 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date.

F3 · derivative.exercise_date: The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date.

F3 · derivative.expiration_date: The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date.

F2 · ownership.nature: The securities reported herein are held of record by Vivo PANDA Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. The Reporting Person is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
February 09, 2021 Filed Feb 9, 2021 20:33 UTC Bolt Biotherapeutics, Inc. BOLT · Entity 8082 ConversionSeries A- 1 Preferred Stock · Derivative 944,056 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-008753 · doc4.xml · derivative · entry 5

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Vivo PANDA Fund, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 944,056 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the "IPO") and had no expiration date.

F1 · derivative.exercise_date: The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the "IPO") and had no expiration date.

F1 · derivative.expiration_date: The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the "IPO") and had no expiration date.

F2 · ownership.nature: The securities reported herein are held of record by Vivo PANDA Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. The Reporting Person is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
February 09, 2021 Filed Feb 9, 2021 20:33 UTC Bolt Biotherapeutics, Inc. BOLT · Entity 8082 SaleCommon Stock 62 $20.00 $1,240.00
Disclosure

SEC source: 0001209191-21-008753 · doc4.xml · nonDerivative · entry 4

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Vivo PANDA Fund, L.P.

Disclosed balance after: 1,448,286

F4 · kind: Upon closing of the Issuer's IPO, Vivo LP exercised a warrant to purchase 17,711 shares of the Issuer's Common Stock at an exercise price per share of $0.07. Vivo LP paid the exercise price on a cashless basis, resulting in the Issuer withholding 62 share subject to the warrant in order to pay the exercise price and issuing to Vivo LP the remaining 17,649 shares of Common Stock.

F2 · ownership.nature: The securities reported herein are held of record by Vivo PANDA Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. The Reporting Person is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
February 09, 2021 Filed Feb 9, 2021 20:33 UTC Bolt Biotherapeutics, Inc. BOLT · Entity 8082 OtherCommon Stock 17,711 $0.07 $1,239.77
Disclosure

SEC source: 0001209191-21-008753 · doc4.xml · nonDerivative · entry 3

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Vivo PANDA Fund, L.P.

Disclosed balance after: 1,448,348

F2 · ownership.nature: The securities reported herein are held of record by Vivo PANDA Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. The Reporting Person is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
February 09, 2021 Filed Feb 9, 2021 20:33 UTC Bolt Biotherapeutics, Inc. BOLT · Entity 8082 ConversionCommon Stock 472,296 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-008753 · doc4.xml · nonDerivative · entry 2

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Vivo PANDA Fund, L.P.

Disclosed balance after: 1,430,637

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date.

F2 · ownership.nature: The securities reported herein are held of record by Vivo PANDA Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. The Reporting Person is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
February 09, 2021 Filed Feb 9, 2021 20:33 UTC Bolt Biotherapeutics, Inc. BOLT · Entity 8082 ConversionCommon Stock 944,056 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-008753 · doc4.xml · nonDerivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Vivo PANDA Fund, L.P.

Disclosed balance after: 958,341

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the "IPO") and had no expiration date.

F2 · ownership.nature: The securities reported herein are held of record by Vivo PANDA Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. The Reporting Person is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
February 01, 2021 Filed Feb 3, 2021 19:10 UTC Verona Pharma plc VRNA · Entity 74409 SaleOrdinary Shares 10,800 $0.99 $10,733.04
Disclosure

SEC source: 0001104659-21-011747 · tm215272-4_4seq1.xml · nonDerivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,760

F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of Restricted Stock Units.

F3 · price: The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $0.99375 to $0.99625. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3.

F4 · balance_after: Consists of (i) 29,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 3,625 ADSs); and (ii) 54,760 Ordinary Shares represented by 6,845 ADSs.

Read SEC document
June 11, 2018 Filed Jun 18, 2018 22:14 UTC SOLENO THERAPEUTICS INC SLNO · Entity 46432 GrantEmployee stock option (right to buy) · Derivative 15,931 $0.00 Strike: $2.04 $0.00
Disclosure

SEC source: 0000899243-18-017052 · doc4.xml · derivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,931

Underlying: Common Stock · 15,931 shares

Expires 2028-06-11

F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary on the Vesting Commencement Date (which is June 11, 2018) or the date of the 2018 Annual Shareholder Meeting, whichever is earlier.

Read SEC document
April 02, 2018 Filed Apr 4, 2018 16:45 UTC Q32 Bio Inc. FIXX · Entity 5594 ConversionSeries B Preferred Stock · Derivative 659,742 $0.00 $0.00
Disclosure

SEC source: 0000899243-18-009459 · doc4.xml · derivative · entry 3

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 659,742 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F2 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F2 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F1 · ownership.nature: The securities reported herein are held of record by Vivo Panda Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D., is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. Each of Vivo LLC and Dr. Shah disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.

Read SEC document
April 02, 2018 Filed Apr 4, 2018 16:45 UTC Q32 Bio Inc. FIXX · Entity 5594 GrantCommon Stock 500,000 $16.00 $8,000,000.00
Disclosure

SEC source: 0000899243-18-009459 · doc4.xml · nonDerivative · entry 2

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,159,742

F1 · ownership.nature: The securities reported herein are held of record by Vivo Panda Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D., is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. Each of Vivo LLC and Dr. Shah disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.

Read SEC document
April 02, 2018 Filed Apr 4, 2018 16:45 UTC Q32 Bio Inc. FIXX · Entity 5594 ConversionCommon Stock 659,742 $0.00 $0.00
Disclosure

SEC source: 0000899243-18-009459 · doc4.xml · nonDerivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 659,742

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The securities reported herein are held of record by Vivo Panda Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D., is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. Each of Vivo LLC and Dr. Shah disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.

Read SEC document
April 02, 2018 Filed May 16, 2018 16:05 UTC Amendment Q32 Bio Inc. FIXX · Entity 5594 GrantCommon Stock 250,000 $16.00 $4,000,000.00
Disclosure

SEC source: 0000899243-18-013061 · doc4a.xml · nonDerivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 909,742

F1 · ownership.nature: The securities reported herein are held of record by Vivo Panda Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D., is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. Each of Vivo LLC and Dr. Shah disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.

Read SEC document
March 27, 2018 Filed Mar 29, 2018 18:30 UTC Q32 Bio Inc. FIXX · Entity 5594 GrantEmployee stock options · Derivative 31,160 $0.00 Strike: $16.00 $0.00
Disclosure

SEC source: 0000899243-18-008909 · doc4.xml · derivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,160

Underlying: Common Stock · 31,160 shares

Expires 2028-03-27

F1 · derivative.exercise_date: The option will vest in three equal annual installments beginning on March 27, 2019.

Read SEC document
February 05, 2018 Filed Feb 8, 2018 01:06 UTC SOLENO THERAPEUTICS INC SLNO · Entity 46432 GrantCommon Stock 3,466 $1.73 $5,983.36
Disclosure

SEC source: 0000899243-18-003162 · doc4.xml · nonDerivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,153

F1 · shares: Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis.

F2 · price: The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on February 2, 2018 or $1.7263.

Read SEC document
October 02, 2017 Filed Oct 4, 2017 22:05 UTC SOLENO THERAPEUTICS INC SLNO · Entity 46432 GrantCommon Stock 11,510 $0.52 $5,985.20
Disclosure

SEC source: 0000899243-17-023583 · doc4.xml · nonDerivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,808

F1 · shares: Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis.

F2 · price: The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on September 29, 2017, or $0.52.

Read SEC document
July 06, 2017 Filed Jul 18, 2017 01:03 UTC SOLENO THERAPEUTICS INC SLNO · Entity 46432 GrantCommon Stock 9,811 $0.61 $5,984.71
Disclosure

SEC source: 0000899243-17-018377 · doc4.xml · nonDerivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,298

F1 · shares: Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis.

F2 · price: The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on July 6, 2017, or $0.61.

Read SEC document
May 08, 2017 Filed May 9, 2017 20:33 UTC SOLENO THERAPEUTICS INC CAPN · Entity 46432 GrantEmployee stock option (right to buy) · Derivative 45,139 $0.00 Strike: $0.72 $0.00
Disclosure

SEC source: 0000899243-17-012478 · doc4.xml · derivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,139

Underlying: Common Stock · 45,139 shares

Expires 2027-05-08

F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary on the Vesting Commencement Date (which is May 8, 2017) or the date of the 2018 Annual Shareholder Meeting, whichever is earlier.

Read SEC document
April 07, 2017 Filed Apr 14, 2017 01:44 UTC SOLENO THERAPEUTICS INC CAPN · Entity 46432 GrantCommon Stock 2,533 $0.63 $1,595.79
Disclosure

SEC source: 0000899243-17-010287 · doc4.xml · nonDerivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,117

F1 · shares: Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis.

F2 · price: The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on April 7, 2017, or $0.63.

Read SEC document
March 07, 2017 Filed Mar 10, 2017 02:52 UTC SOLENO THERAPEUTICS INC CAPN · Entity 46432 GrantEmployee Stock Option · Derivative 20,000 $0.00 Strike: $0.68 $0.00
Disclosure

SEC source: 0000899243-17-007101 · doc4.xml · derivative · entry 2

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2027-03-07

F4 · derivative.exercise_date: One forty-eighth (1/48) of the shares subject to the Option shall vest on the first month anniversary of the Vesting Commencement Date (which is March 7, 2017), and shall continue to vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to Participant continuing to be a Service Provider (as defined in the Plan) through each such date.

Read SEC document
March 07, 2017 Filed Mar 10, 2017 02:52 UTC SOLENO THERAPEUTICS INC CAPN · Entity 46432 GrantCommon Stock 94,584 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-17-007101 · doc4.xml · nonDerivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,584

F1 · shares: The reporting person acquired these securities on March 7, 2017, as consideration for the reporting person's interest as a participant in the management carve-out plan of Essentialis, Inc., which was acquired by the Issuer, through a merger of a wholly-owned subsidiary of Issuer with and into Essentialis on March 7, 2017, pursuant to the Agreement and Plan of Merger dated December 22, 2016, by and among the Issuer, Merger Sub (as defined in the Merger Agreement), Essentialis and the Stockholders Representative (as defined therein) (the "Merger Agreement").

F2 · shares: Continued from Footnote 1 Under the terms of the Merger Agreement, a portion of the merger consideration was held back as partial recourse to satisfy indemnification claims made by the Issuer under the Merger Agreement, and such shares will be issued to former shareholders of Essentialis, participants in Essentialis' management carve-out plan and other service providers of Essentialis, upon the one-year anniversary of the closing of the Merger (subject to the limitations set forth in the Merger Agreement).

F3 · price: Under the terms of Essentialis' management carve-out plan, the number of shares issuable to carve-out plan participants was determined using the closing price per share of Issuer common stock on March 7, 2017, or $0.68.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.